Clinical trial
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children…
NCT02635776 · Aimmune Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT02635776 |
|---|---|
| Title | Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) |
| Official title | Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) |
| Acronym | PALISADE |
| Lead sponsor | Aimmune Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Peanut Allergy |
| Intervention type | Biological |
| Interventions | AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets |
| Enrollment | 555 |
| Start date | Dec 22, 2015 |
| Primary completion | Dec 21, 2017 |
| Completion | Jul 2, 2018 |
| First posted | Dec 21, 2015 |
| Last update posted | Mar 17, 2022 |
| Countries | Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: